Ch. 32 MOA

Question 0

This drug class decreases the production of glucose by the liver, decreases intestinal absorption of glucose, and increases uptake of glucose by tissues. Does not increase insulin secretion from the pancreas.

Answer 0

Biguanides (ie: metformin)

Question 1

Stimulate insulin secretion from the beta cells of the pancreas. Beta cell function must be present. Also improve insulin receptor sensitivity.

Answer 1

Sulfonylureas

Question 2

Increase insulin secretion from the pancreas.

Answer 2

Meglitnides

Question 3

Decrease insulin resistance. Increase glucose uptake and use in skeletal muscle. Inhibit glucose and triglyceride production by the liver.

Answer 3

Thiazolidinediones

Question 4

Reversibly inhibit a specific enzyme in the small intestine which results in a delayed absorption of glucose. Must be taken with meal to prevent postprandial hyperglycemia.

Answer 4

Alpha-glucosidase

Question 5

Slows gastric emptying. Suppresses glucagon secretion which decreases hepatic glucose out put from the liver.

Answer 5

Amylin mimetics

Question 6

Mimic a horomone secreted by the GI tract cells. Inhance glucose driven insulin secretion from beta cells.

Answer 6

Incretin mimetics

Question 7

Lactic acidosis is a rare adverse effect of this medication, but it is lethal if it occurs.

Answer 7

metformin

Question 8

This medication may cause the PT to experience a metallic taste, and can cause reduced B12 levels

Answer 8

metformin

Question 9

This drug class can cause hepatic toxicity and therefore ALT levels must be monitored.

Answer 9

Thiazolidinediones

Question 10

Early symptoms of this condition include: confusion, irritability, tremor, and sweating. Later S&S include: hypothermia and seizures. Coma and death will occur if not treated.

Answer 10

Hypoglycemia